Opaleye Management Inc. grew its stake in shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Rating) by 142.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 535,000 shares of the company’s stock after buying an additional 314,350 shares during the period. Opaleye Management Inc.’s holdings in Theseus Pharmaceuticals were worth $2,664,000 as of its most recent filing with the SEC.
Other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in shares of Theseus Pharmaceuticals by 66.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,420 shares of the company’s stock valued at $26,000 after purchasing an additional 1,757 shares in the last quarter. American International Group Inc. raised its stake in Theseus Pharmaceuticals by 39.2% during the second quarter. American International Group Inc. now owns 7,952 shares of the company’s stock worth $44,000 after acquiring an additional 2,238 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Theseus Pharmaceuticals by 68.3% during the second quarter. JPMorgan Chase & Co. now owns 9,084 shares of the company’s stock worth $50,000 after acquiring an additional 3,687 shares in the last quarter. Forefront Analytics LLC acquired a new stake in shares of Theseus Pharmaceuticals during the 3rd quarter worth about $74,000. Finally, Bank of America Corp DE increased its position in shares of Theseus Pharmaceuticals by 148.0% during the 4th quarter. Bank of America Corp DE now owns 14,620 shares of the company’s stock worth $73,000 after purchasing an additional 8,725 shares in the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.
Wall Street Analysts Forecast Growth
THRX has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Theseus Pharmaceuticals in a research report on Friday, March 10th. Stifel Nicolaus started coverage on shares of Theseus Pharmaceuticals in a report on Wednesday, March 15th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Theseus Pharmaceuticals in a report on Friday, March 10th.
Theseus Pharmaceuticals Trading Down 11.1 %
Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. As a group, equities analysts anticipate that Theseus Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.
Theseus Pharmaceuticals Company Profile
Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.
- Get a free copy of the StockNews.com research report on Theseus Pharmaceuticals (THRX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Want to see what other hedge funds are holding THRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Rating).
Receive News & Ratings for Theseus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.